Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00144794
Other study ID # DIREGC07008
Secondary ID U1111-1294-8266
Status Recruiting
Phase
First received
Last updated
Start date November 20, 2003
Est. completion date January 31, 2034

Study information

Verified date June 2024
Source Sanofi
Contact For site information, send an email with site number to
Email Contact-Us@sanofi.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: - To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase) - To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I - To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care


Description:

The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: - In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com - In Europe - +31-35-699-1232, europe@mpsiregistry.com - In Latin America - +617-591-5500, help@mpsiregistry.com - In North America - +617-591-5500, help@mpsiregistry.com


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date January 31, 2034
Est. primary completion date January 31, 2034
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All patients with a confirmed diagnosis of MPS I are eligible for inclusion. Confirmed diagnosis is defined as: A. documented biochemical evidence of a deficiency in alpha (a)-L-iduronidase enzyme activity and/or B. mutation(s) in the gene coding for a-L-iduronidase, or measurable clinical signs and symptoms of MPS I - For all patients there should be a completed patient authorization form Exclusion Criteria: - No exclusion criteria for participation in the MPS I Registry. NOTE: Registry participation does not exclude participation in other clinical studies.

Study Design


Locations

Country Name City State
Argentina Investigational Site Number : 153130 Buenos Aires
Argentina Investigational Site Number : 153032 Ciudad Autónoma de Buenos Aires Buenos Aires
Australia Investigational Site Number : 152096 Brisbane Queensland
Australia Investigational Site Number : 151069 Westmead New South Wales
Belgium Investigational Site Number : 150944 Brussel
Belgium Investigational Site Number : 150517 Bruxelles
Belgium Investigational Site Number : 151668 Leuven
Belgium Investigational Site Number : 154008 Roeselare
Brazil PUC Campinas - Sociedade Campineira de Educaçao e Instruçao Site Number : 076007 Campinas São Paulo
Brazil Centro de Pesquisa Clínica Prédio 21, 2o andar Hospital de Clínicas de Porto Alegre Site Number : 076001 Porto Alegre Rio Grande Do Sul
Brazil Instituto Fernandes Figueira - FIOCRUZ Site Number : 076004 Rio de Janeiro
Brazil Instituto de Genética e Erros Inatos do Metabolismo - IGEIM Site Number : 076002 São Paulo
Canada Investigational Site Number : 124014 Calgary Alberta
Canada Investigational Site Number : 124002 Edmonton Alberta
Canada Investigational Site Number : 124021 London Ontario
Canada Investigational Site Number : 124022 Moncton New Brunswick
Canada Investigational Site Number : 124018 Montreal Quebec
Canada Investigational Site Number : 124001 Sherbrooke Quebec
Canada Investigational Site Number : 124006 Toronto Ontario
Canada Investigational Site Number : 124011 Vancouver British Columbia
Canada Investigational Site Number : 124019 Winnipeg Manitoba
Chile Investigational Site Number : 152003 Los Angeles
Chile Investigational Site Number : 152001 Talcahuano
Colombia Investigational Site Number : 170001 Bogotá
Croatia Investigational Site Number : 1910001 Zagreb
Czechia Investigational Site Number : 150659 Praha 2
Denmark Investigational Site Number : 151229 København Ø
Egypt Investigational Site Number : 818001 Cairo
Egypt Investigational Site Number : 818002 Cairo
France Investigational Site Number : 250004 Bordeaux
France Investigational Site Number : 250001 BRON Cedex
France Investigational Site Number : 250002 Marseille Cedex 05
France Investigational Site Number : 250003 Paris
France Investigational Site Number : 250005 Paris Cedex 12
France Investigational Site Number : 250006 Vandoeuvre Les Nancy Cedex
Germany Investigational Site Number : 151368 Hamburg
Germany Investigational Site Number : 150031 Mainz
Hong Kong Investigational Site Number : 344001 Kowloon
Hungary Investigational Site Number : 3480005 Pécs
India Investigational Site Number : 356003 Ahmedabad
India Investigational Site Number : 356001 Kolkata
India Investigational Site Number : 3560004 Secunderabad
India Investigational Site Number : 356002 Vellore
Indonesia Investigational Site Number : 360001 Jakarta
Ireland Investigational Site Number : 154161 Dublin
Italy Investigational Site Number : 380002 Ancona
Italy Investigational Site Number : 380004 Cusano Milanino
Italy Investigational Site Number : 380009 Firenze
Italy Investigational Site Number : 380003 Genova
Italy Investigational Site Number : 380007 Milano
Italy Investigational Site Number : 380005 Napoli
Italy Investigational Site Number : 380008 Padova
Italy Investigational Site Number : 380006 Roma
Italy Investigational Site Number : 380001 Udine
Japan Investigational Site Number : 392102 Nangoku-shi Kochi
Japan Investigational Site Number : 392101 Setagaya Tokyo
Korea, Republic of Investigational Site Number : 154286 Changwon-si Gyeongsangnam-do
Korea, Republic of Investigational Site Number : 153191 Daejeon
Korea, Republic of Investigational Site Number : 153225 Jeonnam
Korea, Republic of Investigational Site Number : 151149 Seoul
Korea, Republic of Investigational Site Number : 153180 Seoul
Korea, Republic of Investigational Site Number : 153192 Seoul
Korea, Republic of Investigational Site Number : 153196 Seoul
Korea, Republic of Investigational Site Number : 153212 Seoul
Korea, Republic of Investigational Site Number : 153222 Seoul
Korea, Republic of Investigational Site Number : 154148 Yangsan Gyeongsangnam-do
Korea, Republic of Investigational Site Number : 153178 Yangsan-si Gyeongsangnam-do
Kuwait Investigational Site Number : 154225 Kuwait
Lebanon Investigational Site Number : 4220004 Beirut
Malaysia Investigational Site Number : 458001 Jalan Pahang
Malaysia Investigational Site Number : 458002 Kuala Lumpur
Netherlands Investigational Site Number : 151171 Amsterdam
Netherlands Investigational Site Number : 152029 Rotterdam
Pakistan Investigational Site Number : 154264 Lahore
Pakistan Investigational Site Number : 154266 Lahore
Philippines Investigational Site Number : 608001 Manila
Poland Investigational Site Number : 150575 Warszawa
Portugal Investigational Site Number : 6200002 Coimbra
Romania Investigational Site Number : 154177 Cluj Napoca
Russian Federation Investigational Site Number : 643001 Moscow
Russian Federation Investigational Site Number : 643002 Moscow
Saudi Arabia Investigational Site Number : 682004 Makkah
Saudi Arabia Investigational Site Number : 682001 Qatif
Singapore Investigational Site Number : 702001 Singapore
Slovakia Investigational Site Number : 703001 Bratislava
Sweden Investigational Site Number : 7520001 Stockholm
Taiwan Investigational Site Number : 154093 Chiayi
Taiwan Investigational Site Number : 152152 Hualien
Taiwan Investigational Site Number : 152244 Kaohsiung
Taiwan Investigational Site Number : 152246 Kaohsiung Hsien,
Taiwan Investigational Site Number : 151534 New Taipei City
Taiwan Investigational Site Number : 151500 Putz City, Chia-yi
Taiwan Investigational Site Number : 151181 Taichung
Taiwan Investigational Site Number : 151179 Taichung City
Taiwan Investigational Site Number : 152153 Tainan
Taiwan Investigational Site Number : 153248 Tainan
Taiwan Investigational Site Number : 151182 Taipei
Taiwan Investigational Site Number : 152321 Taipei
Taiwan Investigational Site Number : 153158 Tao Yuan County
Thailand Investigational Site Number : 764001 Bangkok
Thailand Investigational Site Number : 764002 Bangkok
Thailand Investigational Site Number : 764003 Bangkok
Thailand Investigational Site Number : 764004 Bangkok
Thailand Investigational Site Number : 764005 Khon Kaen
United Kingdom Investigational Site Number : 152287 Birmingham
United Kingdom Investigational Site Number : 154240 Birmingham
United Kingdom Investigational Site Number : 152156 Glasgow
United Kingdom Investigational Site Number : 150303 London
United Kingdom Investigational Site Number : 151123 London
United Kingdom Investigational Site Number : 151646 London
United Kingdom Investigational Site Number : 150455 Manchester
United Kingdom Investigational Site Number : 152361 Salford
United States University of Michigan Pediatrics Site Number : 840107 Ann Arbor Michigan
United States Children's Hospital IMD Clinic Site Number : 840069 Aurora Colorado
United States University of Colorado at Denver Genetics Site Number : 840068 Aurora Colorado
United States John Hopkins Site Number : 840044 Baltimore Maryland
United States Boston Children's Hospital Site Number : 840093 Boston Massachusetts
United States Massachusetts General Hospital-Genetics Site Number : 840062 Boston Massachusetts
United States University of Virginia School of Medicine-Pediatrics Site Number : 840078 Charlottesville Virginia
United States Ann and Robert Lurie Children's Hospital Site Number : 840011 Chicago Illinois
United States Rush University Medical Center Genetics Site Number : 840079 Chicago Illinois
United States Cincinnati Children's Hospital-Genetics Site Number : 840041 Cincinnati Ohio
United States UHCMC Site Number : 840119 Cleveland Ohio
United States Nationwide Children's Hospital Site Number : 840091 Columbus Ohio
United States Baylor Research Center Site Number : 840058 Dallas Texas
United States Emory University School of Medicine- Human Genetics Site Number : 840060 Decatur Georgia
United States Children's Hospital of Michigan Site Number : 840066 Detroit Michigan
United States LSD Data Registry Site LLC Site Number : 840094 Dublin Ohio
United States Duke University Medical Center Genetics Dept Site Number : 840037 Durham North Carolina
United States University of Florida Dept of Genetics Site Number : 840083 Gainesville Florida
United States Greenwood Genetcs Site Number : 840055 Greenville South Carolina
United States Joseph M. Sanzari Children's Hospital Site Number : 840101 Hackensack New Jersey
United States Indianapolis University School of Medicine Site Number : 840027 Indianapolis Indiana
United States University of Iowa Site Number : 840032 Iowa City Iowa
United States The Atwal Clinic Site Number : 840112 Jacksonville Florida
United States University of Florida Pediatrics Genetics Site Number : 840121 Jacksonville Florida
United States Children's Specialty Center of Nevada Site Number : 840008 Las Vegas Nevada
United States Arkansas Childrens Hospital Site Number : 840109 Little Rock Arkansas
United States Southern California Permanente Medical Group Site Number : 840108 Los Angeles California
United States USC Health Sciences Center Dept of Genetics Site Number : 840082 Los Angeles California
United States University of Louisville- Genetics Site Number : 840030 Louisville Kentucky
United States Northwell Health Site Number : 840102 Manhasset New York
United States University Of Miami SOM Site Number : 840006 Miami Florida
United States Children's Hospital of Wisconsin-Pediatrics Site Number : 840054 Milwaukee Wisconsin
United States Children's Health Care Site Number : 840114 Minneapolis Minnesota
United States University of Minnesota Medical Center Pediatrics Site Number : 840076 Minneapolis Minnesota
United States Atlantic Health System Site Number : 840099 Morristown New Jersey
United States St. Peter's University Hospital Site Number : 840016 New Brunswick New Jersey
United States Yale Site Number : 840047 New Haven Connecticut
United States Ochsner Medical Center Site Number : 840120 New Orleans Louisiana
United States Metropolitan Hospital Center Site Number : 840110 New York New York
United States New York University School Of Medicine Site Number : 840040 New York New York
United States Children's Hospital of the Kings Daughters Site Number : 840072 Norfolk Virginia
United States Children's Hospital Oakland Site Number : 840029 Oakland California
United States University of Nebraska Medical Center- Pediatrics Site Number : 840084 Omaha Nebraska
United States Children's Hospital of Orange County Site Number : 840074 Orange California
United States Stanford Unviersity MC Dept of Genetics Site Number : 840022 Palo Alto California
United States St. Joseph's Children's Hospital Site Number : 840057 Paterson New Jersey
United States Children's Hospital of Philadelphia HUP Medical Genetics Site Number : 840089 Philadelphia Pennsylvania
United States Children's Hospital of Philadelphia Site Number : 840034 Philadelphia Pennsylvania
United States Phoenix Children's Hospital Site Number : 840003 Phoenix Arizona
United States University of Pittsburgh Site Number : 840023 Pittsburgh Pennsylvania
United States Oregon Health & Science University Site Number : 840080 Portland Oregon
United States Rhode Island Hospital Genetics Site Number : 840053 Providence Rhode Island
United States University of Rochester Medical Center SOM Site Number : 840105 Rochester New York
United States UC Davis MIND Institute Site Number : 840010 Sacramento California
United States Washington University of St. Louis Site Number : 840100 Saint Louis Missouri
United States University of Utah Medical Center Site Number : 840092 Salt Lake City Utah
United States Loma Linda University Children's Hospital Site Number : 840117 San Bernardino California
United States University of California at San Diego Site Number : 840007 San Diego California
United States University of California at San Francisco Site Number : 840051 San Francisco California
United States Seattle Children's Hospital Site Number : 840028 Seattle Washington
United States University Of Washington Medical Center Site Number : 840059 Seattle Washington
United States Baystate Health Site Number : 840002 Springfield Massachusetts
United States State University of New York Site Number : 840052 Syracuse New York
United States Multicare Health System ¿ Mary Bridge Childrens Hospital Site Number : 840115 Tacoma Washington
United States Pediatric Endocrine Associates Site Number : 840017 Tampa Florida
United States Children's National Medical Center Site Number : 840067 Washington District of Columbia
Vietnam Investigational Site Number : 154212 Hanoi
Vietnam Investigational Site Number : 704002 Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
Genzyme, a Sanofi Company

Countries where clinical trial is conducted

United States,  Vietnam,  Argentina,  Australia,  Belgium,  Brazil,  Canada,  Chile,  Colombia,  Croatia,  Czechia,  Denmark,  Egypt,  France,  Germany,  Hong Kong,  Hungary,  India,  Indonesia,  Ireland,  Italy,  Japan,  Korea, Republic of,  Kuwait,  Lebanon,  Malaysia,  Netherlands,  Pakistan,  Philippines,  Poland,  Portugal,  Romania,  Russian Federation,  Saudi Arabia,  Singapore,  Slovakia,  Sweden,  Taiwan,  Thailand,  United Kingdom, 

References & Publications (3)

Arn P, Bruce IA, Wraith JE, Travers H, Fallet S. Airway-related symptoms and surgeries in patients with mucopolysaccharidosis I. Ann Otol Rhinol Laryngol. 2015 Mar;124(3):198-205. doi: 10.1177/0003489414550154. Epub 2014 Sep 11. — View Citation

Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, Fallet S. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014 Oct;16(10):759-65. doi: 10.1038/gim.2014.25. Epub 2014 Mar 27. — View Citation

Viskochil D, Muenzer J, Guffon N, Garin C, Munoz-Rojas MV, Moy KA, Hutchinson DT. Carpal tunnel syndrome in mucopolysaccharidosis I: a registry-based cohort study. Dev Med Child Neurol. 2017 Dec;59(12):1269-1275. doi: 10.1111/dmcn.13545. Epub 2017 Sep 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the long-term effectiveness of Aldurazyme Approximately 17 Years